Alpha 2.0
Login Register
» Authors » Michelle Fuskova

Michelle Fuskova

Explore the profile of Michelle Fuskova including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 2487
Followers 0
Related Specialties
General Medicine
Molecular Biology
Biology
Top 10 Co-Authors
Sagida Bibi
Emma Plested
Parvinder K Aley
Teresa Lambe
Andrew J Pollard
Merryn Voysey
Christina Dold
Pedro M Folegatti
Daniel Jenkin
Simon Kerridge
Published In
Nat Med
Lancet
Nat Commun
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Clemens S, Folegatti P, Emary K, Weckx L, Ratcliff J, Bibi S, et al.
Nat Commun . 2021 Oct; 12(1):5861. PMID: 34615860
Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19...
2.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S, et al.
Nat Med . 2021 Sep; 27(11):2032-2040. PMID: 34588689
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized...
3.
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer K, Barrett J, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al.
Nat Med . 2021 May; 27(6):1116. PMID: 34021278
No abstract available.
4.
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett J, Belij-Rammerstorfer S, Dold C, Ewer K, Folegatti P, Gilbride C, et al.
Nat Med . 2021 May; 27(6):1113. PMID: 33958800
No abstract available.
5.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
Emary K, Golubchik T, Aley P, Ariani C, Angus B, Bibi S, et al.
Lancet . 2021 Apr; 397(10282):1351-1362. PMID: 33798499
Background: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of...
6.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer K, Barrett J, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al.
Nat Med . 2020 Dec; 27(2):270-278. PMID: 33335323
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective vaccines are urgently needed. Strong, Th1-skewed T...
7.
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Barrett J, Belij-Rammerstorfer S, Dold C, Ewer K, Folegatti P, Gilbride C, et al.
Nat Med . 2020 Dec; 27(2):279-288. PMID: 33335322
More than 190 vaccines are currently in development to prevent infection by the novel severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing antibodies against the viral...
8.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D, et al.
Lancet . 2020 Nov; 396(10267):1979-1993. PMID: 33220855
Background: Older adults (aged ≥70 years) are at increased risk of severe disease and death if they develop COVID-19 and are therefore a priority for immunisation should an efficacious vaccine...